Research programme: viral infection therapeutics - Koronis

Drug Profile

Research programme: viral infection therapeutics - Koronis

Alternative Names: KP-1212; SN 1212

Latest Information Update: 05 Jul 2007

Price : $50

At a glance

  • Originator Koronis Pharmaceuticals
  • Class Nucleosides
  • Mechanism of Action Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Hepatitis C; Respiratory syncytial virus infections
  • Discontinued Hepatitis B

Most Recent Events

  • 05 Jul 2007 Discontinued - Preclinical for Hepatitis B in USA (unspecified route)
  • 28 Jun 2007 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)
  • 19 Feb 2004 Preclinical data presented at the 11th Conference on Retroviruses and Opportunistic Infections (CROI-2004) have been added to the adverse events and Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top